Lion Biotechnologies has partnered with the University of Texas MD Anderson to conduct long-running clinical trials of its tumor-infiltrating lymphocyte in the treatment of ovarian cancer, pancreatic cancer, and various sarcomas. The trials will be conducted at MD Anderson, but will be designed by a Lion and MD Anderson steering committee. Lion is hoping to gain data showing promising treatment for many other kinds of cancers in the future. Read the full press release here.